Valuation: Inotiv, Inc.

Market Cap 387K 336K 317K 288K 540K 37.15M 543K 3.79M 1.46M 18.84M 1.45M 1.42M 60.06M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 380M 359M 326M 610M 42.01B 614M 4.28B 1.65B 21.31B 1.65B 1.61B 67.92B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 67 2019-01-11
Director of Finance/CFO 61 2020-03-05
Chief Operating Officer 60 2021-02-14
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-100.00% - - 387K
Average -.--%
Weighted average by Cap. -.--%

Financials

2024 2025
Net sales 491M 425M 402M 365M 684M 47.08B 688M 4.8B 1.85B 23.88B 1.84B 1.8B 76.11B 513M 445M 420M 381M 715M 49.22B 719M 5.02B 1.94B 24.96B 1.93B 1.88B 79.57B
Net income -108M -93.98M -88.83M -80.64M -151M -10.4B -152M -1.06B -410M -5.28B -407M -398M -16.82B -68.62M -59.47M -56.21M -51.03M -95.64M -6.58B -96.21M -671M -259M -3.34B -258M -252M -10.64B
Net Debt 424M 367M 347M 315M 590M 40.65B 594M 4.14B 1.6B 20.62B 1.59B 1.56B 65.71B 438M 379M 358M 325M 610M 41.97B 613M 4.28B 1.65B 21.29B 1.64B 1.61B 67.86B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!